The latest injectable neurotoxin is expected to be widely available in the United States at the end of the month. FDA approved to treat moderate-to-severe glabellar “11” lines in March 2024, Hugel Inc.’s Letybo, (letibotulinumtoxinA-wlbg), also known as Botulax, has been widely used in South Korea and is available in more than 50 countries. 

Allure spoke with a handful of medical aesthetic professionals about their experience with the injectable medication, patient perceptions and market outlook for the product.

Board-certified dermatologist Cheri Frey, MD, has started to use Letybo in her practice. The patients most excited to try it, she said, are those who are looking for alternatives to Botox, who find that it takes longer for the name-brand medication to kick in or who are experiencing neurotoxin resistance. However, board-certified dermatologist Doris Day, MD, told Allure that no neuromodulator has instant onset and that “longevity appears to be comparable to that of Botox, generally lasting about three to four months.”

Board-certified plastic surgeon Roy Kim, MD, told Allure that the newer toxin is expected to have a lower price point, at $9 to $12 per unit for a total cost of $225 to $300 per treatment, compared to $12 to $18 per unit for a total of $300 to $450 for Botox Cosmetic. 

Board-certified dermatologist Ava Shamban, MD, who was a clinical investigator on FDA trials of Letybo, told Allure that the medication has a high efficacy and convincing safety profile. “As a physician, I welcome the introduction of newer toxins with newer manufacturing processes that can deliver a highly purified product that has an excellent safety profile,” said Dr. Shamban.

Read “Everything You Need to Know About Letybo, the Newest Botox Competitor” at Allure >>

Learn more about Neurotoxin Resistance from board-certified head, neck and facial plastic surgeon Steven F. Weiner, MD, on Saturday, April 12, 2025 at Medical Spa Show.